Enterprise Value
-73.68M
Cash
112.3M
Avg Qtr Burn
-12.03M
Short % of Float
0.04%
Insider Ownership
6.52%
Institutional Own.
57.26%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATL001 (TIL cNeT) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 1/2 Data readout | |
ATL001 (cNeT) +/- Nivolumab (anti-PD-1) Details Melanoma, Cancer, Solid tumor/s | Phase 1/2 Data readout |